Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children.
Twenty-three children infected with the human immunodeficiency virus (HIV) were vaccinated with a trivalent inactivated virosomal influenza vaccine. Serum haemagglutinin inhibition antibody titres were determined for the three viral strains at the time of vaccination and 1 month later. CD4 cell counts and HIV viral loads were measured to evaluate the effect of vaccination on HIV status. Adverse reactions were monitored during the first hour following vaccination by an investigator and then on a continuous basis by the parents. Seroconversion rates against the three viral strains A/H3N2, A/H1N1 and B were 73.9%, 56.5% and 52.2%, respectively. Geometric mean antibody titres increased after 1 month compared with baseline values (A/H3N2: 70.9 versus 13.5; A/H1N1: 24.7 versus 5.8; B: 34.4 versus 9.1). No significant changes were observed in either HIV viral load or CD4 cell count following vaccination. Vaccination was well tolerated with only a few mild, transient symptoms.
Zuccotti
G V
GV
Department of Paediatrics, San Paolo Hospital, University of Milan, Italy. zuccottig@libero.it
Zenga
A
A
Durando
P
P
Massone
L
L
Bruzzone
B
B
Sala
D
D
Riva
E
E
D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections; D006679:HIV Seropositivity; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D007251:Influenza, Human / Q000517:prevention & control*; D007558:Italy; D008297:Male; D016896:Treatment Outcome; D014611:Vaccination; D019562:Viral Load
D000914:Antibodies, Viral; D007252:Influenza Vaccines